Status: Recruiting
CAR T Cells in the Treatment of Refractory and Relapsed CD19+ B Cell Neoplasms
One arm, open label study to assess the clinical use of Investigational Medicinal Product FCTX-CL19-1 (scientific name: Tarcidomgen Kimleucel) containing autologous anti-CD19 CAR T cells with a preliminary determination of the safety of intravenous IMP administration in patients diagnosed with refractory and relapsed CD19 + B cell neoplasms.
Participants needed: 6
Trial details
Phase: Phase 1Age: 18-65Biological sex: AllType: InterventionalSponsor: FamiCordTxUpdated: Sep 19, 2024Locations: 2
Eligibility criteria
Adult patients 18-65 both inclusive; [+17]
Any significant CNS diseases that preceded and not connected with relapse (inclu... [+18]